GE HealthCare introduced the MINItrace Magni at the Society of Nuclear Medicine and Molecular Imaging annual meeting (SNMMI) annual meeting, a newly designed, small-footprint cyclotron for in-house production of commercial PET radiotracers.
The boom in theranostics is driving greater demand for gallium-68-based and other PET tracers used to diagnose patients in oncology, cardiology, and neurology, yet the limitations of traditionally used generators have created serious challenges for clinicians and limited patient access, according to the company.
The MINItrace Magni uses solid target technology for in-house production of these tracers, with the company’s TRACERcenter software guiding production, GE said.
Expanded Omni Legend PET/CT
In addition, GE showcased its new Omni Legend 21cm PET/CT scanner, which is pending approval by the U.S. Food and Drug Administration (FDA).
The scanner is a performance-focused PET/CT that offers enhanced image quality in oncology, an ability to accommodate increasing amyloid PET imaging volumes related to Alzheimer's disease, and imaging using fast decay tracers and new tracers in cardiology, the company said.
The system’s 21 cm digital detector offers a 1.6-times increase in system sensitivity compared to the company’s earlier Discovery MI Gen1 20 cm PET/CT system, GE noted. Ultimately, the new Omni Legend scanner is designed to enable clinicians to reduce doses by up to 40% while maintaining exceptional image quality, the company said. Also, the scanner is equipped with Effortless Workflow, AI-based patient auto-positioning software designed to address operational and staffing shortage challenges, GE added.
GE also introduced new deep learning technology for the first time at SNMMI 2023 called Clarify DL. Currently pending approval by the FDA, Clarify DL is image reconstruction software trained on bone SPECT images and designed for the company’s StarGuide digital SPECT/CT system.
Click here for our full SNMMI coverage.
